Singapore at a glance
- Population
- 6.1 million 2025
- Life expectancy at birth
- 83.3 years, 2024
- People aged 65 and over
- 14.2 % of people, 2025
- Health spending per person
- 3,922 US$ per person, 2023
- Doctors
- 2.83 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
Singapore Pet Pharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Product, Animal, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$30.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $28.8 Mn | — | — |
| 2025 (base) | $31.1 Mn | +$2.3 Mn | — |
| 2026 (forecast) | $33.5 Mn | +$2.5 Mn | +7.9% |
| 2027 (forecast) | $36.2 Mn | +$2.6 Mn | +16.4% |
| 2028 (forecast) | $39.0 Mn | +$2.9 Mn | +25.6% |
| 2029 (forecast) | $42.1 Mn | +$3.1 Mn | +35.5% |
| 2030 (forecast) | $45.5 Mn | +$3.3 Mn | +46.3% |
| 2031 (forecast) | $49.1 Mn | +$3.6 Mn | +57.8% |
| 2032 (forecast) | $52.9 Mn | +$3.9 Mn | +70.3% |
| 2033 (forecast) | $57.1 Mn | +$4.2 Mn | +83.7% |
| 2034 (forecast) | $61.6 Mn | +$4.5 Mn | +98.2% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $31.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $61.6 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product and animal (see all) |
| Key players | Zoetis, Inc, Elanco, Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac (see all) |
| Regulator in Singapore | HSASource: Health Sciences Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Pet pharmaceuticals treat dogs, cats and other pets for parasites, pain, allergies, infections and chronic diseases.
Key segments of the pet Pharmaceuticals market include product (Parasiticides, Anti-Inflammatories and Antibiotics) and animal (Dogs, Cats and Others).
More pets per household, owners treating pets as family, livestock disease risks and the One Health approach linking animal and human health are driving the pet Pharmaceuticals market.
Pet insurance, diagnostics and vaccines for emerging animal diseases give the pet Pharmaceuticals market room to grow.
Cost-sensitive farmers, fewer vets in rural areas, rules on antibiotic use in animals and slow approvals hold back the pet Pharmaceuticals market.
The pet Pharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Therapeutic products need registration with the Health Sciences Authority (HSA).[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.[2]
[1] Health Sciences Authority. Checked 14 Nov 2026.
[2] CPF Board, MediShield Life. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pet Pharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.
What doctors and scientists are doing in Pet Pharmaceuticals right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
Singapore · 2 shared keywords
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore · 1 shared keyword
OTC & Nutraceuticals · Singapore
Healthcare Services · Singapore
Medical Devices · Singapore
Digital Health · Singapore
Healthcare Services · Singapore
Public Health · Global